FDA Approves First Ophthalmic Biosimilar With Samsung Bioepis’ Lucentis Rival
Byooviz Ranibizumab Biosimilar Approved; Company Reveals Launch Date Expectations
• By David Wallace
The FDA has approved the Byooviz ranibizumab biosimilar to Lucentis • Source: Alamy 
